Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of the Danish Prospective Sarcoidosis Registry and Baseline Characteristics of a Danish Sarcoidosis Cohort

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04388566
Recruitment Status : Recruiting
First Posted : May 14, 2020
Last Update Posted : May 14, 2020
Sponsor:
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:
Development of a Danish Sarcoidosis Registry. Characterization of a cohort of sarcoidosis patients with respect to the baseline epidemiological characteristics, comorbidities, radiology, histopathology, diagnostic investigations and treatment.

Condition or disease
Sarcoidosis

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: Development of the Danish Prospective Sarcoidosis Registry and Baseline Characteristics of a Danish Sarcoidosis Cohort
Actual Study Start Date : December 1, 2019
Estimated Primary Completion Date : November 30, 2023
Estimated Study Completion Date : November 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sarcoidosis




Primary Outcome Measures :
  1. Characterization of Danish sarcoid patients [ Time Frame: 2 years ]
    Epidemiology and Baseline characteristics of a Danish Sarcoidosis Cohort

  2. Feasibility and completion of a Sarcoidosis Registry. [ Time Frame: 2 years ]
    Development of a Danish sarcoidosis registry Data on epidemiology, clinical characteristics, diagnosis and management will be registered



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Incident patients with sarcoidosis seen in the Department of Respiratory Diseases, Aarhus Denmark
Criteria

Inclusion Criteria:

  • Diagnosis of sarcoidosis
  • Signed informed consent

Exclusion Criteria:

  • Inability or unwillingness to adhere to the study
  • Inability to give informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04388566


Contacts
Layout table for location contacts
Contact: Janne Møller, MD 0045 78462201 jannmoel@rm.dk

Locations
Layout table for location information
Denmark
Aarhus University Hospital Recruiting
Aarhus N, Denmark, 8200
Contact: Janne Møller, MD    0045 78462201    jannmoel@rm.dk   
Sponsors and Collaborators
University of Aarhus

Layout table for additonal information
Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT04388566    
Other Study ID Numbers: SAR1
First Posted: May 14, 2020    Key Record Dates
Last Update Posted: May 14, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoidosis
Lymphoproliferative Disorders
Lymphatic Diseases